首页> 美国卫生研究院文献>Cancer Science >Ritonavir and ixazomib kill bladder cancer cells by causing ubiquitinated protein accumulation
【2h】

Ritonavir and ixazomib kill bladder cancer cells by causing ubiquitinated protein accumulation

机译:Ritonavir和ixazomib通过引起泛素化蛋白质积累杀死膀胱癌细胞

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

There is no curative treatment for advanced bladder cancer. Causing ubiquitinated protein accumulation and endoplasmic reticulum stress is a novel approach to cancer treatment. The HIV protease inhibitor ritonavir has been reported to suppress heat shock protein 90 and increase the amount of unfolded proteins in the cell. If the proteasome functions normally, however, they are rapidly degraded. We postulated that the novel proteasome inhibitor ixazomib combined with ritonavir would kill bladder cancer cells effectively by inhibiting degradation of these unfolded proteins and thereby causing ubiquitinated proteins to accumulate. The combination of ritonavir and ixazomib induced drastic apoptosis and inhibited the growth of bladder cancer cells synergistically. The combination decreased the expression of cyclin D1 and cyclin‐dependent kinase 4, and increased the sub‐G1 fraction significantly. Mechanistically, the combination caused ubiquitinated protein accumulation and endoplasmic reticulum stress. The combination‐induced apoptosis was markedly attenuated by the protein synthesis inhibitor cycloheximide, suggesting that the accumulation of ubiquitinated proteins played an important role in the combination's antineoplastic activity. Furthermore, the combination induced histone acetylation cooperatively and the decreased expression of histone deacetylases was thought to be one mechanism of this histone acetylation. The present study provides a theoretical basis for future development of novel ubiquitinated‐protein‐accumulation‐based therapies effective against bladder cancer.
机译:目前尚无治疗晚期膀胱癌的方法。引起泛素化蛋白积累和内质网应激是癌症治疗的一种新方法。据报道,HIV蛋白酶抑制剂利托那韦可抑制热激蛋白90并增加细胞中未折叠蛋白的数量。但是,如果蛋白酶体正常运行,它们会迅速降解。我们推测新型蛋白酶体抑制剂ixazomib与利托那韦合用可通过抑制这些未折叠蛋白的降解从而使泛素化蛋白积聚来有效杀死膀胱癌细胞。利托那韦和艾沙佐米联合使用可诱导细胞凋亡,并协同抑制膀胱癌细胞的生长。该组合降低了细胞周期蛋白D1和细胞周期蛋白依赖性激酶4的表达,并显着增加了sub-G1分数。从机理上讲,这种结合导致泛素化蛋白积累和内质网应激。组合诱导的细胞凋亡被蛋白质合成抑制剂环己酰亚胺显着减弱,表明泛素化蛋白的积累在组合的抗肿瘤活性中起着重要作用。此外,该组合协同诱导组蛋白乙酰化,并且组蛋白脱乙酰基酶表达的降低被认为是该组蛋白乙酰化的机制之一。本研究为有效开发针对膀胱癌的新的基于泛素化蛋白蓄积的新疗法提供了理论基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号